First Analysis of a Phase II Study of Rituximab-Gemcitabine, Cyclophosphamide, Vincristine and Prednisolone (R-GCVP) for Diffuse Large B Cell Lymphoma (DLBCL) Patients Considered Unsuitable for Anthracycline Containing Chemo-Immunotherapy. An NCRI Lymphoma Clinical Studies Group Trial

Paul Fields; Andrew Webb; Christopher F. E. Pocock; William Townsend; Paul Smith; Amy Kirkwood; Nadjet El-Mehidi; Peter W. Johnson; John Radford; David C. Linch; David Cunningham

doi:10.1182/blood.V118.21.1634.1634

First Analysis of a Phase II Study of Rituximab-Gemcitabine, Cyclophosphamide, Vincristine and Prednisolone (R-GCVP) for Diffuse Large B Cell Lymphoma (DLBCL) Patients Considered Unsuitable for Anthracycline Containing Chemo-Immunotherapy. An NCRI Lymphoma Clinical Studies Group Trial

Paul Fields, Andrew Webb, Christopher F. E. Pocock, William Townsend, Paul Smith, Amy Kirkwood, Nadjet El-Mehidi, Peter W. Johnson, John Radford, David C. Linch, David Cunningham

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Blood
DOIs	https://doi.org/10.1182/blood.V118.21.1634.1634
Publication status	Published - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1182/blood.V118.21.1634.1634

Cite this

Fields, P., Webb, A., Pocock, C. F. E., Townsend, W., Smith, P., Kirkwood, A., El-Mehidi, N., Johnson, P. W., Radford, J., Linch, D. C., & Cunningham, D. (2011). First Analysis of a Phase II Study of Rituximab-Gemcitabine, Cyclophosphamide, Vincristine and Prednisolone (R-GCVP) for Diffuse Large B Cell Lymphoma (DLBCL) Patients Considered Unsuitable for Anthracycline Containing Chemo-Immunotherapy. An NCRI Lymphoma Clinical Studies Group Trial. Blood. https://doi.org/10.1182/blood.V118.21.1634.1634

@article{4a72bc66b5bb4106968cf268ed933109,

title = "First Analysis of a Phase II Study of Rituximab-Gemcitabine, Cyclophosphamide, Vincristine and Prednisolone (R-GCVP) for Diffuse Large B Cell Lymphoma (DLBCL) Patients Considered Unsuitable for Anthracycline Containing Chemo-Immunotherapy. An NCRI Lymphoma Clinical Studies Group Trial",

author = "Paul Fields and Andrew Webb and Pocock, {Christopher F. E.} and William Townsend and Paul Smith and Amy Kirkwood and Nadjet El-Mehidi and Johnson, {Peter W.} and John Radford and Linch, {David C.} and David Cunningham",

year = "2011",

doi = "10.1182/blood.V118.21.1634.1634",

language = "English",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier BV",

}

Fields, P, Webb, A, Pocock, CFE, Townsend, W, Smith, P, Kirkwood, A, El-Mehidi, N, Johnson, PW, Radford, J, Linch, DC & Cunningham, D 2011, 'First Analysis of a Phase II Study of Rituximab-Gemcitabine, Cyclophosphamide, Vincristine and Prednisolone (R-GCVP) for Diffuse Large B Cell Lymphoma (DLBCL) Patients Considered Unsuitable for Anthracycline Containing Chemo-Immunotherapy. An NCRI Lymphoma Clinical Studies Group Trial', Blood. https://doi.org/10.1182/blood.V118.21.1634.1634

First Analysis of a Phase II Study of Rituximab-Gemcitabine, Cyclophosphamide, Vincristine and Prednisolone (R-GCVP) for Diffuse Large B Cell Lymphoma (DLBCL) Patients Considered Unsuitable for Anthracycline Containing Chemo-Immunotherapy. An NCRI Lymphoma Clinical Studies Group Trial. / Fields, Paul; Webb, Andrew; Pocock, Christopher F. E. et al.
In: Blood, 2011.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - First Analysis of a Phase II Study of Rituximab-Gemcitabine, Cyclophosphamide, Vincristine and Prednisolone (R-GCVP) for Diffuse Large B Cell Lymphoma (DLBCL) Patients Considered Unsuitable for Anthracycline Containing Chemo-Immunotherapy. An NCRI Lymphoma Clinical Studies Group Trial

AU - Fields, Paul

AU - Webb, Andrew

AU - Pocock, Christopher F. E.

AU - Townsend, William

AU - Smith, Paul

AU - Kirkwood, Amy

AU - El-Mehidi, Nadjet

AU - Johnson, Peter W.

AU - Radford, John

AU - Linch, David C.

AU - Cunningham, David

PY - 2011

Y1 - 2011

UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000299597102229&KeyUID=WOS:000299597102229

U2 - 10.1182/blood.V118.21.1634.1634

DO - 10.1182/blood.V118.21.1634.1634

M3 - Article

SN - 0006-4971

JO - Blood

JF - Blood

ER -

Fields P, Webb A, Pocock CFE, Townsend W, Smith P, Kirkwood A et al. First Analysis of a Phase II Study of Rituximab-Gemcitabine, Cyclophosphamide, Vincristine and Prednisolone (R-GCVP) for Diffuse Large B Cell Lymphoma (DLBCL) Patients Considered Unsuitable for Anthracycline Containing Chemo-Immunotherapy. An NCRI Lymphoma Clinical Studies Group Trial. Blood. 2011. doi: 10.1182/blood.V118.21.1634.1634

First Analysis of a Phase II Study of Rituximab-Gemcitabine, Cyclophosphamide, Vincristine and Prednisolone (R-GCVP) for Diffuse Large B Cell Lymphoma (DLBCL) Patients Considered Unsuitable for Anthracycline Containing Chemo-Immunotherapy. An NCRI Lymphoma Clinical Studies Group Trial

UN SDGs

Access to Document

Other files and links

Cite this